Alterity Therapeutics (ATHE) Competitors $3.42 -0.03 (-0.72%) Closing price 05/2/2025 03:50 PM EasternExtended Trading$3.39 -0.03 (-1.02%) As of 05/2/2025 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHE vs. NMRA, SCPH, RAPT, ENTA, OGI, CHRS, CTNM, CCCC, ALEC, and TNXPShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Neumora Therapeutics (NMRA), scPharmaceuticals (SCPH), RAPT Therapeutics (RAPT), Enanta Pharmaceuticals (ENTA), Organigram (OGI), Coherus BioSciences (CHRS), Contineum Therapeutics (CTNM), C4 Therapeutics (CCCC), Alector (ALEC), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. Neumora Therapeutics scPharmaceuticals RAPT Therapeutics Enanta Pharmaceuticals Organigram Coherus BioSciences Contineum Therapeutics C4 Therapeutics Alector Tonix Pharmaceuticals Alterity Therapeutics (NASDAQ:ATHE) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Which has more volatility and risk, ATHE or NMRA? Alterity Therapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.89, suggesting that its share price is 189% more volatile than the S&P 500. Does the MarketBeat Community prefer ATHE or NMRA? Neumora Therapeutics received 24 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 76.32% of users gave Neumora Therapeutics an outperform vote while only 62.50% of users gave Alterity Therapeutics an outperform vote. CompanyUnderperformOutperformAlterity TherapeuticsOutperform Votes562.50% Underperform Votes337.50% Neumora TherapeuticsOutperform Votes2976.32% Underperform Votes923.68% Do institutionals and insiders believe in ATHE or NMRA? 2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 26.4% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ATHE or NMRA more profitable? Alterity Therapeutics' return on equity of 0.00% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A Neumora Therapeutics N/A -73.63%-68.97% Do analysts prefer ATHE or NMRA? Alterity Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 250.36%. Neumora Therapeutics has a consensus target price of $9.29, suggesting a potential upside of 1,096.30%. Given Neumora Therapeutics' higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Alterity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22 Does the media refer more to ATHE or NMRA? In the previous week, Alterity Therapeutics had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 3 mentions for Alterity Therapeutics and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.59 beat Alterity Therapeutics' score of -0.08 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, ATHE or NMRA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$12.54MN/AN/ANeumora TherapeuticsN/AN/A-$235.93M-$1.53-0.51 SummaryNeumora Therapeutics beats Alterity Therapeutics on 7 of the 13 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.37M$6.85B$5.56B$8.03BDividend YieldN/A2.96%5.09%4.23%P/E RatioN/A7.5022.7518.87Price / SalesN/A259.05405.66106.84Price / CashN/A65.8538.1834.62Price / Book3.296.566.794.34Net Income-$12.54M$143.63M$3.22B$248.06M7 Day Performance-1.58%3.35%3.36%3.18%1 Month Performance16.89%10.29%6.92%8.28%1 Year Performance67.07%-3.67%16.16%5.04% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics1.8237 of 5 stars$3.43-0.7%$12.00+250.4%+61.6%$30.37MN/A0.0010Short Interest ↑News CoverageNMRANeumora Therapeutics3.1947 of 5 stars$0.76+0.7%$9.29+1,117.6%-91.6%$123.35MN/A-0.41108SCPHscPharmaceuticals3.7234 of 5 stars$2.45-2.4%$14.00+471.4%-44.2%$123.20M$36.33M-1.2930News CoverageRAPTRAPT Therapeutics4.255 of 5 stars$0.92+4.8%$4.00+334.3%-88.1%$121.59M$1.53M-0.3380Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap DownENTAEnanta Pharmaceuticals4.0512 of 5 stars$5.63+0.9%$17.25+206.4%-57.2%$120.11M$66.59M-1.14160Upcoming EarningsNews CoveragePositive NewsOGIOrganigram0.4639 of 5 stars$1.12-3.4%N/A-38.8%$120.04M$166.12M-2.95860CHRSCoherus BioSciences3.5457 of 5 stars$1.03flat$5.26+410.9%-49.3%$119.37M$266.96M-12.88330Upcoming EarningsAnalyst ForecastNews CoverageCTNMContineum Therapeutics2.0059 of 5 stars$4.50+2.0%$24.80+451.1%-72.5%$116.42M$50M-0.9231CCCCC4 Therapeutics2.4605 of 5 stars$1.62+5.2%$12.50+671.6%-72.9%$115.03M$35.58M-0.95150Upcoming EarningsNews CoverageALECAlector3.6868 of 5 stars$1.16+1.8%$3.50+201.7%-75.7%$114.94M$100.56M-0.68270Upcoming EarningsNews CoveragePositive NewsTNXPTonix Pharmaceuticals2.2565 of 5 stars$17.03-4.4%$585.00+3,335.1%-96.3%$109.59M$10.09M0.0050Short Interest ↑ Related Companies and Tools Related Companies NMRA Competitors SCPH Competitors RAPT Competitors ENTA Competitors OGI Competitors CHRS Competitors CTNM Competitors CCCC Competitors ALEC Competitors TNXP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHE) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATHE Stock Free ATHE Stock Alerts